Skip to Main Content

INFORMATION FOR

    Michael Paidas, MD

    Professor Adjunct
    DownloadHi-Res Photo

    About

    Titles

    Professor Adjunct

    Biography

    Dr. Paidas is the recipient of The David J. Leffell, M.D. Prize for Clinical Excellence at Yale in 2010, given to one member of Yale Medicine annually. In 2012, Dr. Paidas received the Dean’s Award from the Tufts Medical Alumni Association. Dr. Paidas is included in the top 1% physician by specialty in the nation according to US News and World Report. He has been recognized by the March of Dimes and is included in Best Doctors in America. Dr. Paidas has also received the National Faculty Award by the Counsel on Resident Education in Obstetrics and Gynecology.

    Dr. Paidas received his medical degree from Tufts University School of Medicine in 1987 and completed his internship and residency in Obstetrics and Gynecology in 1991 at Pennsylvania Hospital. In 1993, Dr. Paidas completed a Fellowship in Maternal Fetal Medicine at the Mount Sinai School of Medicine in New York. In 2013, Dr. Paidas was awarded a Master of Arts, Honorary Degree, from Yale University.

    Dr. Paidas's career in medicine has focused on women’s health with special emphasis on blood disorders, reproduction, pregnancy complications and the latter’s impact on health and disease. His activities span direct patient care, translational research and clinical trials. Dr. Paidas’s research has been supported by federal and non- federal funding agencies. His notable contributions include: description of the regulatory factors of the Protein C system; clinical use of recombinant antithrombin in disease states; elucidation of the subsequent cardiovascular and non-cardiovascular health consequences of hypertensive disorders and preterm delivery in the largest population based studies published to date.

    Dr. Paidas and collaborators have described the genomic and proteomic effects of Preimplantation Factor (PIF), a novel mammalian embryo derived factor which regulates maternal receptivity to pregnancy and possesses key immune modulatory properties. Subsequent animal studies using a synthetic analogue of native PIF have shown benefit in animal models related to a variety of immune diseases, including multiple sclerosis and graft versus host disease.

    Dr. Paidas is the lead Principal Investigator of a multicenter preeclampsia treatment clinical trial, entitled Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1).

    Dr. Paidas has expertise in prenatal ultrasound, invasive fetal diagnostic and therapeutic procedures. His academic profile includes over 500 published manuscripts, abstracts, books, chapters, presentations or courses.

    Education & Training

    MA
    Yale University, Honorary Degree (2013)
    Fellow
    Mount Sinai Medical Center (1993)
    Resident
    Pennsylvania Hospital (1991)
    MD
    Tufts University School of Medicine (1987)
    BS
    Fairfield University (1982)

    Research

    Overview

    Dr. Paidas’s notable contributions include: description of the regulatory factors of the Protein C system; clinical use of recombinant antithrombin in disease states; elucidation of the subsequent cardiovascular and non-cardiovascular health consequences of hypertensive disorders and preterm delivery in the largest population based studies published to date.

    Dr. Paidas and collaborators have described the genomic and proteomic effects of Preimplantation Factor (PIF), a novel mammalian embryo derived factor which regulates maternal receptivity to pregnancy and possesses key immune modulatory properties. Subsequent animal studies using a synthetic analogue of native PIF have shown benefit in animal models related to a variety of immune diseases, including multiple sclerosis and graft versus host disease.

    Dr. Paidas is the lead Prinicipal Investigator of a multicenter preeclampsia treatment clinical trial, entitled Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1).

    Dr. Paidas has expertise in prenatal ultrasound, invasive fetal diagnostic and therapeutic procedures. His academic profile includes over 500 published manuscripts, abstracts, books, chapters, presentations or courses.

    “Multigate Doppler with Global Acquisition and Signal Processing (G.A.S.P.) in the uteroplacental and fetal circulations.” This new non-invasive Doppler ultrasound technology is being applied to a variety of areas concerning women’s health, including early pregnancy assessment and gynecologic malignancy screening. This project is a collaboration between the Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Department of Obstetrics and Gynecology; University of Milan, Bicocca, Milan, Italy; Department of Engineering, University of Florence, Florence, Italy; Esaote, Florence, Italy.

    “Antithrombin levels preceding placenta mediated complications.” The objective of this study is to determine antithrombin and Preimplantation Factor levels in pregnancy complications, prior to the onset of clinical disease.

    “Preimplantation factor (PIF): a biomarker for viable embryo selection after in vitro fertilization and for pregnancy outcome.” This proposal is a multicenter study which investigates the potential role of Preimplantation Factor as a diagnostic test in two settings; namely, to predict IVF success when measured in embryo culture media, and to predict viable pregnancy and a range of placenta mediated complications.

    “Predicting Late and Early Perinatal Stroke in High Risk Pregnancies And High Risk Neonates.” The goal is to identify a very high risk population for perinatal stroke suitable for prevention or early treatment.

    “Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Pre-term Pre-eclampsia (PRESERVE-1): RB AT PPE-01-13. Funding Agency: rEVO Biologics (formerly GTC Biotherapeutics). This is a multicenter, randomized, placebo controlled trial to determine whether maternal administration of recombinant antithrombin will prolong gestational age in the setting of preeclampsia at 24 to less than 28 wks.

    “Neural Stem Cells and synthetic Preimplantation Factor (sPIF) to treat perinatal brain injury in the rodent. PreImplantation-Factor (PIF) +/- neural stem cells will be investigated as a therapeutic option to treat perinatal brain injury.

    Medical Research Interests

    Abruptio Placentae; Antithrombin III Deficiency; Blood Coagulation Disorders, Inherited; Diseases; Pre-Eclampsia; Pregnancy Complications; Pregnancy Complications, Cardiovascular; Pregnancy Complications, Hematologic; Preimplantation Diagnosis; Thrombocytopenia, Neonatal Alloimmune; Thrombophilia

    Research at a Glance

    Yale Co-Authors

    Frequent collaborators of Michael Paidas's published research.

    Publications

    2024

    Academic Achievements & Community Involvement

    • activity

      Society for Maternal Fetal Medicine

    • activity

      International Stillbirth Alliance

    • activity

      Centers for Disease Control

    • activity

      National Institutes of Health

    • activity

      Canadian Institutes of Health Research